RegulatoryJun 15, 2026, 06:26 AM
SINOVAC Regains Nasdaq Global Market Listing Compliance
AI Summary
Sinovac Biotech Ltd. announced it received a notification from Nasdaq, confirming it has regained compliance with Listing Rule 5250(c)(1) and is now in compliance with the Nasdaq Global Market's listing requirements. The company remains under a Mandatory Panel Monitor pursuant to Listing Rule 5815(d)(4)(B) until May 20, 2027. This compliance follows the filing of its annual report on Form 20-F for the year ended December 31, 2025, on June 5, 2026, leading to the cancellation of the scheduled hearing.
Key Highlights
- SINOVAC regained compliance with Nasdaq Listing Rule 5250(c)(1).
- Company is now in compliance with Nasdaq Global Market's listing requirements.
- Remains under a Mandatory Panel Monitor until May 20, 2027.
- Filed annual report on Form 20-F for the year ended December 31, 2025, on June 5, 2026.
- Hearing before the Nasdaq Hearings Panel was accordingly canceled.
Price Impact
More from SVA